CNBC April 4, 2024
Karen Gilchrist

Key Points

– The CEO of French consumer goods giant Danone on Wednesday downplayed the threat of obesity drugs on its food business.

– Antoine de Saint-Affrique told CNBC that surging demand for drugs like Wegovy and Mounjaro would increase consumer appetite for nutritional products.

– “We see ourselves as extremely complementary to GLP-1s,” de Saint-Affrique told CNBC’s Charlotte Reed.

The CEO of French consumer goods giant Danone downplayed the threat of obesity drugs on its food business, arguing that consumers were likely to turn to healthy products as part of their new weight loss regime.

Antoine de Saint-Affrique said that surging demand for drugs like Wegovy and Mounjaro would only increase consumer appetite for more nutritional products.

“We see...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Pharma / Biotech, Provider, Retailer
How AI Is Quietly Transforming E-Commerce Search And Discovery
Walmart's '24 healthcare exit: 10 notes
What big retailers did in healthcare in 2024
How Trauma-Informed Design Principles Can Be Health-Ful for All of Us – Learning from IKEA
Walmart health and wellness leader to exit role

Share This Article